Vir Biotechnology, Inc. — Director's Dealing 2019

Oct 17, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2019-10-16

Reporting Person: SVF Endurance (Cayman) Ltd (10% Owner)
Reporting Person: SB INVESTMENT ADVISERS (UK) LTD (10% Owner)
Reporting Person: SOFTBANK VISION FUND (AIV M1) L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-10-16	Common Stock, par value $0.0001 per share	C	21666666	—	Acquired	21666666	Indirect
2019-10-16	Common Stock, par value $0.0001 per share	P	950000	$20.00	Acquired	22616666	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-10-16	Series A-1 Convertible Preferred Stock	$	C	15555555	Disposed		Common Stock (15555555)	Indirect
2019-10-16	Series B Convertible Preferred Stock	$	C	6111111	Disposed		Common Stock (6111111)	Indirect

Footnotes

F1: The Series A-1 Convertible Preferred Stock and the Series B Convertible Preferred Stock each converted into Vir Biotechnology, Inc. common stock on a one-to-one basis and had no expiration date.

F2: Represents securities held directly by SVF Endurance (Cayman) Limited. SVF Endurance (Cayman) Limited is a wholly-owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.

F3: (continued from footnote 2) SBIA UK is wholly owned by SoftBank Group Corp. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose.